The phenylalkanoic acid derivative, flurbiprofen (2-[2-fluoro-4-biphenylyl]propionic acid), is a nonsteroidal drug with antiinflammatory, antipyretic, and analgesic properties. The biological activity of flurbiprofen appears to be based on its activity as a modifier of arachidonic acid metabolism, resulting in a significant inhibition of prostaglandin (PG) biosynthesis. Studies in a variety of in vivo and in vitro systems have found flurbiprofen to be 2-20 times more potent than indomethacin in inhibiting PGE2 production (Brogden et al., 1979; Boots, 1981) .
Flurbiprofen inhibits PG biosynthesis by inhibiting the cyclooxygenase component of PG synthetase (Nozu, 1978) ; this enzyme catalyzes the transformation of arachidonic acid into PG endoperoxides, which are then further metabolized to form PGs and thromboxanes. However, limited evidence suggests that flurbiprofen may also inhibit the lipoxygenase pathway of arachidonic acid metabolism (Higgs et al., 1980) ; lipoxygenase is not involved in PG synthesis, but does modulate the production of leukotrienes and hydroperoxy and hydroxy fatty acids.
Previous studies have shown that flurbiprofen has significant therapeutic activity when administered to animals bearing transplantable tumours. In studies with the NC mammary adenocarcinoma, Bennett and colleagues demonstrated that administration of flurbiprofen can both inhibit the growth of primary transplanted tumours (Leaper et al., 1979) , and increase mean survival time in mice following resection of the primary lesion (Bennett et al., 1982) . In the same model system, flurbiprofen enhanced the chemotherapeutic activity of methotrexate or melphalan (Berstock et al., 1979; Bennett et al., 1982 (McCormick & Moon, 1983b) . The present study was performed to determine if, in addition to its therapeutic activity against established tumours, flurbiprofen can also inhibit mammary carcinogenesis when administered prior to tumour appearance.
Mammary carcinomas were induced in female Sprague-Dawley rats by a single injection of Nmethyl-N-nitrosourea (MNU) as previously described in detail (McCormick et al., 1981) . Crystalline MNU (Ash-Stevens, Detroit, MI) was dissolved in sterile saline solution (pH 5.0) immediately prior to use. At 50 days of age, rats were lightly anaesthesized with ether and received a single injection of 50mg or 25mg MNU per kg body weight via the jugular vein. Control animals received an injection of sterile saline solution only.
One week after MNU administration, animals were randomized into experimental groups by weight (Table I) . At this time, administration of control diet (Wayne Lab Meal, Allied Mills, Chicago, IL), or control diet supplemented with 62.5 or 31.25mg flurbiprofen kg-l diet was begun. Flurbiprofen was a generous gift of Dr. Paul Bresloff, Boots Co., Ltd., Nottingham; dose levels of flurbiprofen were chosen to provide a dose of approximately 5.0 or 2.5mg kg-1 body wt per day.
Beginning 4 weeks after MNU administration, animals were palpated twice weekly to monitor mammary tumour appearance. Animals were observed twice daily and weighed weekly throughout the study. At 180 days after MNU administration, the experiment was terminated and all animals were killed by CO2 asphyxiation. All mammary tumours and any other grossly abnormal tissues were removed and prepared for histopathological classification. Only histologically-confirmed mammary cancers (adenocarcinomas and papillary carcinomas) were used in the data analysis.
Intravenous administration of MNU induced mammary cancers in a dose-related manner. In group 3, which received a dose of 50 mg MNU kg-I body wt and the control diet, the first mammary tumour became palpable at 36 days after carcinogen administration; cancer incidence reached ©) The Macmillan Press Ltd., 1983 50% by 67 days, and was 100% at 97 days post-MNU. In group 6, which received the 25 mg MNU kg-1 dose and the control diet, the first palpable mammary lesion appeared at 60 days, and a 50% cancer incidence was reached at 112 days after MNU administration. In addition to increased incidence with a shorter tumour latent period, the high MNU dose induced -3 times as many cancers per rat as did the low MNU dose (Table I) .
The influence of flurbiprofen on mammary carcinogenesis was a function of carcinogen dose. At the high MNU dose, flurbiprofen had no activity as an inhibitor of carcinogenesis in terms of cancer incidence, carcinoma multiplicity, or tumour latent period. Final cancer incidence was 100% in all groups receiving 50mg MNU kg-1, regardless of the presence or absence of the flurbiprofen dietary supplement. Similarly, all groups had -6.2 mammary cancers per animal. No effect of flurbiprofen on tumour latency was found at this MNU dose: time to 50% cancer incidence (T50) was 67 days in the control group, and 60 and 70 days in the low and high flurbiprofen groups, respectively. By contrast, flurbiprofen had significant activity as an inhibitor of mammary carcinogenesis induced by the low dose of MNU. Administration of flurbiprofen at both 62.5 and 31.25 mg kg-1 diet dose levels reduced mammary carcinoma multiplicity by 1/3 compared to control (P<0.05). Cancer incidence was also influenced by flurbiprofen treatment, as incidence was reduced from 91% in the diet control group to 60 and 68% in the two flurbiprofen groups. Although a trend towards increased median tumour latency was observed with flurbiprofen administration (T50= 112 days in the control group versus 130 and 133 days in flurbiprofen groups), this increase was not statistically significant.
The reasons for the effect of carcinogen dose on the chemopreventive activity of flurbiprofen are unknown. Little data exist to suggest a differential biology for tumours of the same histological type induced by different doses of carcinogen, although Rose et al. (1980) have reported that mammary cancers induced by a high dose MNU regimen (3 doses of 50mgkg-1) are less sensitive to oestrogen withdrawal than are cancers induced by a lower total MNU dose (2 doses of 50mgkg-1). Thus, the possibility does exist that tumours with a short latent period may be less responsive to modulation, in effect "overwhelming" the influence of the modifier. Support for such a view comes from our studies with indomethacin. In animals treated with a dose of carcinogen (8mg 7,12-dimethylbenz(a)anthracene, DMBA) comparable to the low dose of MNU used in this study, two dose levels of indomethacin both inhibited mammary cancer induction. By contrast, at a carcinogen dose (16mg DMBA) comparable to the high dose of MNU, the low indomethacin dose had no effect on cancer response, while the high dose retained its anticarcinogenic efficacy (McCormick & Moon, 1983b; McCormick, unpublished) .
Flurbiprofen inhibited mammary carcinogenesis without toxicity. As indicated in Table I The inhibition of mammary carcinogenesis by inhibitors of arachidonic acid metabolism such as flurbiprofen is consistent with studies performed in other experimental tumour models, notably mouse skin -and rat colon (Verma et al., 1980; Pollard & Luckert, 1981; Narisawa et al., 1981) . The mechanism(s) by which these agents inhibit cancer induction are unknown, although influences on cell kinetics (Bayer et al., 1979; Boynton & Whitfield, 1980) , mammary gland differentiation (MiyamotoTiaven et al., 1981; McCormick & Moon, 1983b) , and immune function (Droller et al., 1978; Glaser, 1980) may be involved. These data indicate that modulation of arachidonic acid metabolism is a mechanism through which mammary carcinogenesis can be inhibited in experimental animals. Further study is required to determine the role of specific eicosanoids (PGs, thromboxanes, leukotrienes, and hydroperoxy and hydroxy fatty acids) in mammary cancer induction, and to elucidate the mechanisms by which modification of arachidonic acid metabolism inhibits carcinogenesis.
